XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENT INFORMATION (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Reportable Segment Information
The following table includes information about segment revenue, significant segment expenses, and segment measure of profitability:
Three Months Ended
June 30,		  Six Months Ended
June 30,
20252024  20252024
Total revenues$825,410 $712,029 $1,570,555 $1,360,862 
Less:
Cost of sales150,090 130,459 301,648 255,639 
R&D expenses
Research and early pipeline95,968 106,063 186,438 226,455 
Later-stage clinical programs13,133 7,714 27,424 7,714 
Marketed products52,207 70,010 106,177 154,605 
SG&A expenses
S&M expenses122,100 122,798 224,631 242,158 
G&A expenses110,179 140,234 213,764 246,780 
Other segment expense, net (1)
41,201 27,577 84,255 31,675 
Net income$240,532 $107,174 $426,218 $195,836 
(1)Other segment expense, net during the three months ended June 30, 2025 and 2024 include intangible asset amortization, interest income and expense, other income (expense) and income tax expense.
Schedule of Disaggregation of Total Net Product Revenues by Product
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
VOXZOGO$221,391 $183,923 $435,145 $336,812 
VIMIZIM215,424 178,016 403,770 370,536 
NAGLAZYME128,867 132,049 243,157 237,678 
PALYNZIQ105,938 88,291 199,207 164,000 
ALDURAZYME56,437 38,558 105,414 73,820 
BRINEURA48,692 45,309 89,054 84,356 
KUVAN27,034 28,551 52,170 64,461 
ROCTAVIAN9,199 7,432 19,709 8,281 
Total net product revenues812,982 702,129 1,547,626 1,339,944 
Royalty and other revenues12,428 9,900 22,929 20,918 
Total revenues$825,410 $712,029 $1,570,555 $1,360,862 
Schedule of Disaggregation of Total Net Product Revenues by Geographic Region The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is distributed, marketed and sold exclusively by Sanofi worldwide.
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
United States$272,554 $227,449 $514,248 $420,448 
Europe243,138 220,990 472,716 416,738 
Latin America98,118 84,418 186,400 163,012 
Rest of world142,735 130,714 268,848 265,926 
Total net product revenues marketed by the Company$756,545 $663,571 $1,442,212 $1,266,124 
ALDURAZYME net product revenues marketed by Sanofi56,437 38,558 105,414 73,820 
Total net product revenues$812,982 $702,129 $1,547,626 $1,339,944 
Schedule of Total Net Product Revenue Concentrations Attributed to Largest Customers
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
Customer A15 %14 %15 %14 %
Customer B12 11 12 11 
Customer C11 10 11 9 
Total38 %35 %38 %34 %